Latest Quarterly Report
Filed: 2026-05-01
Key Insights
- Boston Scientific completed multiple strategic acquisitions in Q1 2026, including Penumbra Inc. (January 15), Nalu Medical (January 27), and Scivita Medical, indicating aggressive portfolio expansion and M&A activity to strengthen competitive positioning.
- The filing demonstrates active hedging strategies across foreign exchange contracts and net investment hedges, suggesting management is managing currency exposure and international operational risks as the company operates globally.
- The company maintains structured debt obligations including Senior Notes due 2027 and December 2027 Notes, requiring careful cash flow management and refinancing planning in the near-term maturity window.
- Significant intangible assets related to acquisitions, including technology-based intangibles, patents, and in-process R&D, indicate substantial goodwill and integration risk that could impact future earnings if synergy targets are not achieved.